Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 11/20 | 0.79 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802752 | 1.00 | DAPK3 (0.79) | DAPK3ALOX5GAAMAPTNOTUM | |
| SCHEMBL6795284 | 0.88 | DAPK3 (0.71) | DAPK3ALOX5GAAMAPTNOTUM | |
| SCHEMBL6795280 | 0.88 | DAPK3 (0.71) | DAPK3ALOX5GAAMAPTNOTUM | |
| SCHEMBL6795935 | 0.83 | DAPK3 (0.64) | DAPK3ALOX5GAAMAPTNOTUM | |
| SCHEMBL6795940 | 0.83 | DAPK3 (0.64) | DAPK3ALOX5GAAMAPTNOTUM | |
| SCHEMBL29517925 | 0.83 | PLCG2 (0.69) | DAPK3ALOX5MAPTNOTUMMAPK1 | |
| SCHEMBL6796902 | 0.81 | DAPK3 (0.58) | DAPK3ALOX5MAPTNOTUMMEN1 | |
| SCHEMBL6796899 | 0.81 | DAPK3 (0.58) | DAPK3ALOX5MAPTNOTUMMEN1 | |
| SCHEMBL6801419 | 0.75 | DAPK3 (0.64) | DAPK3ALOX5GAAMAPTNOTUM | |
| SCHEMBL6801416 | 0.75 | DAPK3 (0.64) | DAPK3ALOX5GAAMAPTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180943-A1 | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis | WARNER-LAMBERT COMPANY LLC | 2004-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180943-A1 | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis | APP, PSEN1, PSEN2 | DAPK3 1049/4885ALOX5 1156/4885GAA 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.